Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promising agents for treating Alzheimer's disease

W Simonson1

  • 1Center for Health Information, Chesapeake, VA 23321, USA. wsimonson@chamberlaingrp.com

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|November 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardizing Ecosystem Morphological Traits from 3D Information Sources.

Trends in ecology & evolution·2020
Same author

Rel B is an early marker of autoimmune islet inflammation in the biobreeding (BB) rat.

Pancreas·2000
Same author

Medication use by community-dwelling elderly with urinary incontinence.

Urologic nursing·1999
Same author

Drug therapy implications on activity: a focus on the elderly patient.

Nurse practitioner forum·1996
Same author

Validation of two methods of data collection of self-reported medicine use among the elderly.

The Gerontologist·1988
Same author

Geriatric pharmacy curriculum in U.S. pharmacy schools, 1985-86.

Gerontology & geriatrics education·1987
Same journal

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Pharmacotherapy for Alzheimer's disease (AD) faces challenges including adverse reactions and symptom management. Cholinesterase inhibitors (ChEIs) are current mainstays, but combination therapies show future promise for improved cognitive and behavioral outcomes.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Alzheimer's disease (AD) pharmacotherapy requires addressing adverse reactions, comorbidities, and comprehensive symptom management.
  • Current treatments primarily focus on enhancing cholinergic function.

Purpose of the Study:

  • To discuss key issues in Alzheimer's disease pharmacotherapy.
  • To review current and investigational pharmacologic agents for AD.
  • To explore future directions in AD drug discovery and treatment.

Main Methods:

  • Review of current literature on Alzheimer's disease pharmacotherapy.
  • Description of established and experimental therapeutic agents.
  • Discussion of challenges and future strategies in AD drug development.

Related Experiment Videos

Main Results:

  • Cholinesterase inhibitors (ChEIs), such as donepezil, are the primary FDA-approved agents demonstrating efficacy in improving cognitive and behavioral symptoms.
  • Investigational agents include selective muscarinic agonists, antioxidants, anti-inflammatory drugs, and estrogen replacement therapy.
  • Future pharmacotherapy likely involves combination treatments utilizing ChEIs with agents targeting other pathogenic pathways.

Conclusions:

  • Effective pharmacotherapy for Alzheimer's disease must balance efficacy with safety and address a spectrum of symptoms.
  • Cholinesterase inhibitors remain crucial, but novel therapeutic strategies and combination approaches are essential for advancing AD treatment.
  • Ongoing research into AD pathogenesis is critical for developing more targeted and effective future treatments.